

Martin Andreas RÃ¼der

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2403816/publications.pdf>

Version: 2024-02-01

113
papers

4,208
citations

257450

24
h-index

128289

60
g-index

123
all docs

123
docs citations

123
times ranked

7534
citing authors

#	ARTICLE	IF	CITATIONS
1	Exercise training to increase tumour natural killer cell infiltration in men with localised prostate cancer: a randomised controlled trial. <i>BJU International</i> , 2023, 131, 116-124.	2.5	16
2	Selective arterial embolization of renal angiomyolipomas: A 10-year experience. <i>BJUI Compass</i> , 2022, 3, 86-92.	1.3	5
3	Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study. <i>BJU International</i> , 2022, 130, 102-113.	2.5	19
4	Long-Term Renal Function Following Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2022, 160, 147-153.	1.0	11
5	Center experience and other determinants of patient radiation exposure during prostatic artery embolization: a retrospective study in three Scandinavian centers. <i>European Radiology</i> , 2022, 32, 2404-2413.	4.5	4
6	Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. <i>Cancer Causes and Control</i> , 2022, , 1.	1.8	2
7	Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 149-154.	1.0	3
8	A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup. <i>Journal of Urology</i> , 2022, 208, 100-108.	0.4	10
9	Reply to Djaladat H and Choreifi A's Letter-to-the-Editor Re: Vejlggaard M, Maibom SL, Stroomberg HV, et al. Long-term Renal Function Following Radical Cystectomy for Bladder Cancer. <i>Urology</i> . 2021;S0090-4295(21)01083-9. doi:10.1016/j.urology.2021.11.015. <i>Urology</i> , 2022, , .	1.0	0
10	Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1795-1801.	3.1	8
11	Reply by Authors. <i>Journal of Urology</i> , 2022, , 101097JU000000000000249103.	0.4	0
12	Prostatic artery embolization in men with severe hemophilia a: a case report of two patients. <i>CVIR Endovascular</i> , 2022, 5, 21.	1.1	0
13	Quality of life and secondary outcomes for open versus robot-assisted radical cystectomy: a double-blinded, randomised feasibility trial. <i>World Journal of Urology</i> , 2022, 40, 1669-1677.	2.2	8
14	Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis. <i>Acta Oncologica</i> , 2022, 61, 931-938.	1.8	1
15	Risk of Depression After Radical Prostatectomy – A Nationwide Registry-based Study. <i>European Urology Oncology</i> , 2021, 4, 601-608.	5.4	13
16	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2021, 62, 354-359.	5.0	16
17	Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. <i>Acta Oncologica</i> , 2021, 60, 316-322.	1.8	20
18	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264

#	ARTICLE	IF	CITATIONS
19	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1290.	3.7	17
20	The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy – a nationwide study. <i>Acta Oncologica</i> , 2021, 60, 620-626.	1.8	0
21	Safety and oncological outcome following radiofrequency ablation of small renal masses in a single center. <i>Scandinavian Journal of Urology</i> , 2021, 55, 203-208.	1.0	3
22	Short-term morbidity and mortality following radical cystectomy: a systematic review. <i>BMJ Open</i> , 2021, 11, e043266.	1.9	48
23	Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. <i>European Urology Open Science</i> , 2021, 28, 1-8.	0.4	17
24	Risk of depression after diagnostic prostate cancer workup – a nationwide, registry-based study. <i>Psycho-Oncology</i> , 2021, 30, 1939-1947.	2.3	7
25	Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. <i>Urology</i> , 2021, 155, 20-25.	1.0	4
26	Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial – the “DEXAPAE”™ study. <i>BMJ Open</i> , 2021, 11, e047878.	1.9	1
27	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
28	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
29	AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. <i>Diagnostics</i> , 2020, 10, 520.	2.6	1
30	The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 877.	2.6	2
31	Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. <i>PLoS ONE</i> , 2020, 15, e0238814.	2.5	4
32	Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 659.	2.6	16
33	Can Computed Tomography Perfusion Predict Treatment Response After Prostate Artery Embolization: A Feasibility Study. <i>Diagnostics</i> , 2020, 10, 304.	2.6	1
34	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. <i>Scientific Reports</i> , 2020, 10, 10704.	3.3	8
35	What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review. <i>BMJ Open</i> , 2020, 10, e040965.	1.9	4
36	Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. <i>European Radiology</i> , 2019, 29, 287-298.	4.5	98

#	ARTICLE	IF	CITATIONS
37	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. <i>American Journal of Pathology</i> , 2019, 189, 2377-2388.	3.8	16
38	Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 222-228.	1.0	1
39	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e814-e821.	1.9	12
40	Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1405-1412.	2.0	21
41	Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery. <i>Diagnostics</i> , 2019, 9, 46.	2.6	16
42	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1025.	4.1	4
43	Educational level and first-time PSA testing in general practice. <i>Scandinavian Journal of Urology</i> , 2019, 53, 275-281.	1.0	9
44	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 595-608.	7.0	55
45	Risk of depression following prostate cancer work-up: A nationwide study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5061-5061.	1.6	0
46	The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis. <i>Scandinavian Journal of Urology</i> , 2018, 52, 169-173.	1.0	2
47	Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer – A population-based analysis of 2 national cohorts. <i>Cancer</i> , 2018, 124, 2931-2938.	4.1	58
48	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.3	153
49	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. <i>European Urology Focus</i> , 2018, 4, 360-368.	3.1	7
50	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e181-e192.	1.9	4
51	Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. <i>Scandinavian Journal of Urology</i> , 2018, 52, 1-7.	1.0	9
52	The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis. <i>Scandinavian Journal of Urology</i> , 2018, 52, 358-363.	1.0	8
53	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	12.8	43
54	Predictive value of combined analysis of pro-NGP and ERG in localized prostate cancer. <i>Apmis</i> , 2018, 126, 804-813.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
56	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
57	Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 221-229.	10.7	54
58	The drama of prostate cancer diagnostics – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e133.	10.7	1
59	Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer. <i>Journal of Clinical Pathology</i> , 2017, 70, 1063-1068.	2.0	1
60	Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. <i>Surgical Oncology</i> , 2017, 26, 21-27.	1.6	8
61	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. <i>European Urology Focus</i> , 2017, 3, 646-649.	3.1	72
62	The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2017, 51, 450-456.	1.0	18
63	Diagnostic characteristics of lethal prostate cancer. <i>European Journal of Cancer</i> , 2017, 84, 18-26.	2.8	31
64	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 171-171.	1.6	0
65	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 12-12.	1.6	0
66	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 12-12.	1.6	0
67	Diagnostic characteristics of men harboring lethal prostate cancer: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 217-217.	1.6	0
68	Antibiotic prophylaxis and complications following prostate biopsies - a systematic review. <i>Danish Medical Journal</i> , 2017, 64, .	0.5	0
69	Danish Prostate Cancer Registry – methodology and early results from a novel national database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 351-360.	3.0	25
70	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading – a matched-pair analysis. <i>BJU International</i> , 2016, 117, 883-889.	2.5	19
71	PD26-01 CHANGES IN CLINICO-PATHOLOGICAL CHARACTERISTICS AT PROSTATE CANCER DIAGNOSIS DETECTED ON PROSTATE BIOPSIES IN DANISH MEN FROM 1995 TO 2011. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
72	Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?. <i>Scandinavian Journal of Urology</i> , 2016, 50, 135-143.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , 2016, 6, 23.	2.5	37
74	Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results. <i>Biomarkers in Medicine</i> , 2016, 10, 209-216.	1.4	11
75	Anastomotic complications after robot-assisted laparoscopic and open radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 274-279.	1.0	13
76	A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e1-291.e7.	1.6	10
77	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. <i>Prostate</i> , 2015, 75, 1499-1509.	2.3	11
78	Active surveillance for localized prostate cancer: An analysis of patient contacts and utilization of healthcare resources. <i>Scandinavian Journal of Urology</i> , 2015, 49, 43-50.	1.0	14
79	ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 788-794.	2.0	8
80	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. <i>Scandinavian Journal of Urology</i> , 2015, 49, 275-281.	1.0	2
81	Urokinase plasminogen activator receptor (uPAR) as a novel biomarker in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 183-183.	1.6	0
82	Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2014, 48, 168-176.	1.0	11
83	Non-epical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence. <i>Journal of Surgical Oncology</i> , 2014, 109, 818-822.	1.7	6
84	Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. <i>BJU International</i> , 2014, 113, 541-547.	2.5	18
85	Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2014, 109, 132-138.	1.7	9
86	Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. <i>BJU International</i> , 2014, 113, E98-105.	2.5	11
87	Active surveillance for clinically localized prostate cancer – A systematic review. <i>Journal of Surgical Oncology</i> , 2014, 109, 830-835.	1.7	139
88	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. <i>Scandinavian Journal of Urology</i> , 2014, 48, 268-275.	1.0	59
89	Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: Can nerve-sparing surgery increase the risk?. <i>Scandinavian Journal of Urology</i> , 2014, 48, 15-20.	1.0	9
90	Changes in preoperative characteristics in patients undergoing radical prostatectomy – a 16-year nationwide analysis. <i>Acta Oncologica</i> , 2014, 53, 361-367.	1.8	10

#	ARTICLE	IF	CITATIONS
91	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
92	ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2014, 66, 851-860.	1.9	75
93	PD27-12 BIOCHEMICAL EFFICACY OF ENZALUTAMIDE IN POST-CHEMO MCRPC PATIENTS PREVIOUSLY TREATED WITH ABIRATERONE. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
94	MP70-19 KETOCONAZOLE THERAPY IN POST-CHEMO MCRPC - THE CASE FOR A COMPARISON TO ABIRATERONE. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
95	MP62-20 ESTIMATED LENGTH OF LIFE GAINED WITH RADICAL PROSTATECTOMY COMPARED TO THE BACKGROUND POPULATION: A POPULATION-BASED ANALYSIS. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
96	994 STANDARDIZED RELATIVE SURVIVAL AND MORTALITY AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
97	Radical prostatectomy in clinically localized high-risk prostate cancer: Outcome of 231 consecutive patients. <i>Scandinavian Journal of Urology</i> , 2013, 47, 19-25.	1.0	6
98	Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?. <i>Apmis</i> , 2013, 121, 257-265.	2.0	13
99	996 NATION-WIDE ANALYSIS OF SURVIVAL AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN DENMARK 1995-2011. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
100	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	21.4	492
101	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013, 22, 408-415.	2.9	118
102	Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. <i>Danish Medical Journal</i> , 2013, 60, A4575.	0.5	32
103	Patients undergoing radical prostatectomy have a better survival than the background population. <i>Danish Medical Journal</i> , 2013, 60, A4612.	0.5	5
104	Radical prostatectomy for clinically localised prostate cancer at Rigshospitalet 1995-2011 - an analysis of surgical and oncological outcome. <i>Danish Medical Journal</i> , 2013, 60, B4752.	0.5	1
105	First danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 172-179.	1.4	7
106	Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. <i>BJU International</i> , 2012, 109, 520-524.	2.5	31
107	Response to: K B Bell, M Kida & K Cooper: Histopathology sampling of radical prostatectomy specimens: representative or entire submission?. <i>Histopathology</i> , 2011, 59, 1014-1014.	2.9	0
108	Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation. <i>Apmis</i> , 2011, 119, 239-246.	2.0	18

#	ARTICLE	IF	CITATIONS
109	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011, 43, 785-791.	21.4	265
110	First Danish Single-Institution Experience with Radical Prostatectomy: Biochemical Outcome in 1200 Consecutive Patients. <i>Prostate Cancer</i> , 2011, 2011, 1-5.	0.6	13
111	A case of iatrogenic ureteric injury presenting with headache. <i>Nature Reviews Urology</i> , 2008, 5, 113-116.	1.4	1
112	The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 361-369.	2.4	12
113	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8